NeoClone Through a lot of hard work, a license from the Wisconsin Alumni Research Foundation (WARF) and a desire to have an impact on human health, our company was founded in 1999 by three University of Wisconsin scientists who recognized the need for better ways to discover and develop antibodies. As they refined the process to make better antibodies (what is now the NeoAb process), they established a reagent catalog as well as a service business to make high-quality antibodies for others. By 2002 the founders realized a need to bring in business expertise to help grow the company by leveraging its ability to make excellent antibodies. This change in direction is the foundation of what the company is today - a company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostics. As a result of these efforts, we now haave over 700 customers in 30+ countries. To poise ourselves for future success, we continue to refine our antibody making abilities so we can make fully human antibodies and service the rapidly growing therapeutics market. We have had a research team focused on this effort for the past seven years and we are confident that we will be offering these services, using our patented and proprietary approach, to the market in 2011.